Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01742039
NCT01742039
Completed
Not Applicable

A New Therapeutic Strategy to Reduce the Incidence of Postoperative Atrial Fibrillation

George Washington University2 sites in 1 country160 target enrollmentJuly 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPostoperative Atrial Fibrillation

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Postoperative Atrial Fibrillation
Sponsor
George Washington University
Enrollment
160
Locations
2
Primary Endpoint
occurrence of atrial fibrillation
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The primary aim of this study is to determine the safest and most effective therapeutic strategy to decrease the incidence of postoperative atrial fibrillation following cardiac surgery in an era with shorter ICU and hospital length of stay. A secondary goal is to evaluate the length of hospital stay associated with each treatment strategy.

Registry
clinicaltrials.gov
Start Date
July 2008
End Date
June 2011
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •age \> or = to 18 years
  • •sinus rhythm
  • •undergoing either coronary artery bypass graft surgery (CABG), valvular heart surgery or a combined procedure

Exclusion Criteria

  • •received a class-I or class-III antiarrhythmic agent in the past six months
  • •had second or third degree heart block
  • •had a resting heart rate of less than 50 beats per minute
  • •had a systolic blood pressure less than 100 mmHg
  • •had severe asthma or severe chronic obstructive pulmonary disease
  • •had uncontrolled heart failure
  • •had a serum aspartate aminotransferase or alanine aminotransferase concentration greater than four times the upper limit of normal

Outcomes

Primary Outcomes

occurrence of atrial fibrillation

Time Frame: postoperative day 0-day of discharge (an average of 5 days)

The primary endpoint of this study was the occurrence of atrial fibrillation lasting longer than five minutes

Secondary Outcomes

  • length of stay(participants will be followed for the duration of hospital stay, an expected average of 5 days)

Study Sites (2)

Loading locations...

Similar Trials

Completed
Not Applicable
A study to find the most effective treatment strategy to suppress dementia progression in cardiovascular disease associated diabetic patientsCardiovascular disease, dementia
JPRN-UMIN000029923Kitasato University Graduate School
Recruiting
Phase 1
Establishing Best Treatment Strategy for T4 Esophageal CancerEsophageal Cancer TNM Staging Primary Tumor (T) T4
NCT06531434National Cheng-Kung University Hospital22
Recruiting
Not Applicable
Development of novel treatment strategy to prevent progression of arteriosclerosis in dialysis patientsend stage renal disease
JPRN-UMIN000020384second department of internal medicine, Kansai Medical University Hirakata hospital100
Not yet recruiting
Phase 4
Stopping Pneumonia Antibiotherapy Regimen EarlyCommunity-acquired PneumoniaChild, Only
NCT06291012University Hospital, Montpellier1,100
Terminated
Phase 2
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung CancerNon-small Cell Lung Cancer
NCT00200382Rasim Gucalp27